BioLight Announces Start of Clinical Study with DiagnosTear Dry Eye Syndrome Diagnostic Assay

BioLight announced that DiagnosTear Ltd. has received all necessary approvals from Sheba Medical Center near Tel Aviv to begin a clinical study with its TeaRx, point-of-care Dry Eye Syndrome diagnostic assay.

The purpose of the study is to validate the effectiveness of the test methods developed by DiagnosTear in the tears of healthy subjects as well as patients with Dry Eye Syndrome.

Link to the complete article

 

Link to Newsroom

Comments are closed